„Reverse Remodeling” - Paradigmenwechsel in der Behandlung der pulmonalen Hypertonie

Schlüsselwörter

Reverse Modeling - Remodeling - Pulmonale Hypertonie

Key words

reverse modeling - remodeling - pulmonary hypertension

Literatur

• 1 Ali F Y, Egan K, Fitzgerald G A, Desvergne B, Wahli W, Bishop-Bailey D, Warner T D, Mitchell J A. Role of Prostacyclin Receptor Versus PPAR{beta} with Treprostinil Sodium on Lung Fibroblast Proliferation.  Am J Respir Cell Mol Biol. 2005;  20 242-246
• 2 Barst R J, Rubin L J, Long W A, McGoon M D, Rich S, Badesch D B, Groves B M, Tapson V F, Bourge R C, Brundage B H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med. 1996;  334 296-302
• 3 Botney M D. Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension.  Am J Respir Crit Care Med. 1999;  159 361-364
• 4 Dorfmuller P, Humbert M, Capron F, Muller K M. Pathology and aspects of pathogenesis in pulmonary arterial hypertension.  Sarcoidosis Vasc Diffuse Lung Dis. 2003;  20 9-19
• 5 Galie N, Ghofrani H A, Torbicki A, Barst R J, Rubin L J, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2005;  353 2148-2157
• 6 Galie N, Seeger W, Naeije R, Simonneau G, Rubin L J. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  (12 Suppl S) 43 81S-88S
• 7 Ghofrani H A, Reichenberger F, Kohstall M G, Mrosek E H, Seeger T, Olschewski H, Seeger W, Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.  Ann Intern Med. 2004;  141 169-177
• 8 Ghofrani H A, Rose F, Schermuly R T, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
• 9 Ghofrani H A, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension.  N Engl J Med. 2005;  353 1412-1413
• 10 Ghofrani H A, Wiedemann R, Rose F, Olschewski H, Schermuly R T, Weissmann N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.  Ann Intern Med. 2002;  136 515-522
• 11 Ghofrani H A, Wiedemann R, Rose F, Schermuly R T, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.  Lancet. 2002;  360 895-900
• 12 Grosser T, Bonisch D, Zucker T P, Schror K. Iloprost-induced inhibition of proliferation of coronary artery smooth muscle cells is abolished by homologous desensitization.  Agents Actions Suppl. 1995;  45 85-91
• 13 Hassoun P M, Thappa V, Landman M J, Fanburg B L. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells.  Proc Soc Exp Biol Med. 1992;  199 165-170
• 14 Haworth S G. Pulmonary vascular remodeling in neonatal pulmonary hypertension. State of the art.  Chest. 1988;  (Suppl 3) 93 133S-138S
• 15 Hoeper M M, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 100710-10
• 16 Lane K B, Machado R D, Pauciulo M W, Thomson J R, Phillips J A, Loyd J E, Nichols W C, Trembath R C. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium.  Nat Genet. 2000;  26 81-84
• 17 Lee S D, Shroyer K R, Markham N E, Cool C D, Voelkel N F, Tuder R M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.  J Clin Invest. 1998;  101 927-934
• 18 Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.  Am J Respir Crit Care Med. 2000;  161 487-492
• 19 Morse J H, Jones A C, Barst R J, Hodge S E, Wilhelmsen K C, Nygaard T G. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.  Circulation. 1997;  95 2603-2606
• 20 Nichols W C, Koller D L, Slovis B, Foroud T, Terry V H, Arnold N D, Siemieniak D R, Wheeler L, Phillips J A, Newman J H, Conneally P M, Ginsburg D, Loyd J E. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32.  Nat Genet. 1997;  15 277-280
• 21 Olschewski H, Ghofrani H A, Schmehl T, Winkler J, Wilkens H, Hoper M M, Behr J, Kleber F X, Seeger W. German PPH Study Group . Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial.  Ann Intern Med. 2000;  132 435-443
• 22 Olschewski H, Ghofrani H A, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.  Am J Respir Crit Care Med. 1999;  160 600-607
• 23 Olschewski H, Rose F, Grunig E, Ghofrani H A, Walmrath D, Schulz R, Schermuly R, Grimminger F, Seeger W. Cellular pathophysiology and therapy of pulmonary hypertension.  J Lab Clin Med. 2001;  138 367-377
• 24 Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L J, Nikkho S, Speich R, Hoeper M M, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani H A, Manes A, Kiely D G, Ewert R, Meyer A, Corris P A, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 25 Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L J, Nikkho S, Speich R, Hoeper M M, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani H A, Manes A, Kiely D G, Ewert R, Meyer A, Corris P A, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 26 Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.  Ann Intern Med. 1996;  124 820-824
• 27 Rubin L J. Primary pulmonary hypertension.  N Engl J Med. 1997;  336 111-117
• 28 Rubin L J, Badesch D B, Barst R J, Galie N, Black C M, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 29 Schermuly R T, Dony E, Ghofrani H A, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai Y J, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition.  J Clin Invest. 2005;  115 2811-2821
• 30 Schermuly R T, Kreisselmeier K P, Ghofrani H A, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.  Am J Respir Crit Care Med. 2004;  169 39-45
• 31 Simonneau G, Barst R J, Galie N, Naeije R, Rich S, Bourge R C, Keogh A, Oudiz R, Frost A, Blackburn S D, Crow J W, Rubin L J. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double- blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
• 32 Simonneau G, Galie N, Rubin L J, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  (12 Suppl S) 43 5S-12S
• 33 Stenmark K R, Mecham R P. Cellular and molecular mechanisms of pulmonary vascular remodeling.  Annu Rev Physiol. 1997;  59 89-144
• 34 Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Md A B, Galie N. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.  Basic Res Cardiol. 2005;  100 131-138
• 35 Wensel R, Opitz C F, Ewert R, Bruch L, Kleber F X. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension.  Circulation. 2000;  101 2388-2392
• 36 Williamson D J, Wallman L L, Jones R, Keogh A M, Scroope F, Penny R, Weber C, Macdonald P S. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.  Circulation. 2000;  102 411-418
• 37 Wort S J, Mitchell J A, Woods M, Evans T W, Warner T D. The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells.  J Cardiovasc Pharmacol. 2000;  (5 Suppl 1) 36 S410-S413
• 38 Yi E S, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen L A, Park K, Friedman P J. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study.  Am J Respir Crit Care Med. 2000;  162 1577-1586